Pfizer Breaks With Biosimilars In China Through WuXi Bio Deal

Pfizer China To Also Offload Manufacturing Site In Hangzhou

Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.

China globe
The agreement for the biologics site in Hangzhou is expected to close in the first half of 2021 • Source: Shutterstock

Pfizer has made the “difficult decision” to draw a line under its biosimilar endeavors in China, agreeing to sell its biologics manufacturing site in Hangzhou to local biologics contract development and manufacturing firm WuXi Biologics and halt its biosimilar programs in the country.

The agreement, which is expected to close in the first half of 2021, and new strategic direction followed “a comprehensive...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.